Literature DB >> 16026308

Signal transduction activated by cannabinoid receptors.

Inés Díaz-Laviada1, Lidia Ruiz-Llorente.   

Abstract

Since the discovery that cannabinoids exert biological actions through binding to specific receptors, signal mechanisms triggered by these receptors have been focus of extensive study. This review summarizes the current knowledge of the signalling events produced by cannabinoids from membrane receptors to downstream regulators. Two types of cannabinoid receptors have been identified to date: CB(1) and CB(2) both belonging to the heptahelichoidal receptor family but with different tissue distribution and signalling mechanisms. Coupling to inhibitory guanine nucleotide-binding protein and thus inhibition of adenylyl cyclase has been observed in both receptors but other signal transduction pathways that are regulated or not by these G proteins are differently activated upon ligand-receptor binding including ion channels, sphingomyelin hydrolysis, ceramide generation, phospholipases activation and downstream targets as MAP kinase cascade, PI3K, FAK or NOS regulation. Cannabinoids may also act independently of CB(1)or CB(2) receptors. The existence of new unidentified putative cannabinoid receptors has been claimed by many investigators. Endocannabinoids activate vanilloid TRPV1 receptors that may mediate some of the cannabinoid effects. Other actions of cannabinoids can occur through non-receptor-mediated mechanisms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16026308     DOI: 10.2174/1389557054368808

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  12 in total

1.  Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.

Authors:  Amy K Dickason-Chesterfield; Stephanie R Kidd; Steven A Moore; John M Schaus; Bin Liu; George G Nomikos; Christian C Felder
Journal:  Cell Mol Neurobiol       Date:  2006-05-31       Impact factor: 5.046

Review 2.  Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences.

Authors:  J M McPartland; M Glass; R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-07-16       Impact factor: 8.739

3.  Mastering tricyclic ring systems for desirable functional cannabinoid activity.

Authors:  Ravil R Petrov; Lindsay Knight; Shao-Rui Chen; Jim Wager-Miller; Steven W McDaniel; Fanny Diaz; Francis Barth; Hui-Lin Pan; Ken Mackie; Claudio N Cavasotto; Philippe Diaz
Journal:  Eur J Med Chem       Date:  2013-09-29       Impact factor: 6.514

Review 4.  The endocannabinoid system in prostate cancer.

Authors:  Inés Díaz-Laviada
Journal:  Nat Rev Urol       Date:  2011-09-13       Impact factor: 14.432

5.  The cannabinoid WIN 55212-2 mitigates apoptosis and mitochondrial dysfunction after hypoxia ischemia.

Authors:  D Alonso-Alconada; A Alvarez; F J Alvarez; J A Martínez-Orgado; E Hilario
Journal:  Neurochem Res       Date:  2011-09-11       Impact factor: 3.996

Review 6.  Signal transduction via cannabinoid receptors.

Authors:  George D Dalton; Caroline E Bass; C G Van Horn; Allyn C Howlett
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

Review 7.  An overview on the biochemistry of the cannabinoid system.

Authors:  María Gómez-Ruiz; Mariluz Hernández; Rosario de Miguel; Jose A Ramos
Journal:  Mol Neurobiol       Date:  2007-06-30       Impact factor: 5.590

8.  Selective inhibition of alpha/beta-hydrolase domain 6 attenuates neurodegeneration, alleviates blood brain barrier breakdown, and improves functional recovery in a mouse model of traumatic brain injury.

Authors:  Flaubert Tchantchou; Yumin Zhang
Journal:  J Neurotrauma       Date:  2013-04-05       Impact factor: 5.269

9.  Disruption of IFN-gamma- mediated antiviral activity in neurons: the role of cannabinoids.

Authors:  R Antonio Herrera; Joseph H Oved; Carol Shoshkes Reiss
Journal:  Viral Immunol       Date:  2008-06       Impact factor: 2.257

10.  Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.

Authors:  N Olea-Herrero; D Vara; S Malagarie-Cazenave; I Díaz-Laviada
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.